Give ATV with food at least 2 hours before and at least 10 hours after the H2RA.ĭo not coadminister unboosted ATV plus H2RA in PI-experienced patients. When Given 2 Hours Before and ≥10 Hours After H2RAĪ single dose of H2RA should not exceed a dose equivalent to famotidine 20 mg, and the total daily dose should not exceed a dose equivalent to famotidine 20 mg twice daily in PI-naive patients. When Given Simultaneously With Famotidine Food and Drug Administration product labels for information regarding drug interactions between these PIs and concomitant medications.Įffect on PI and/or Concomitant Drug Concentrationsĭosing Recommendations and Clinical CommentsĪdminister ATV at least 2 hours before or 2 hours after antacids or buffered medications. Note: FPV, NFV, and TPV are no longer commonly used in clinical practice and are not included in this table. In cases where an interacting drug needs to be replaced with an alternative, providers should exercise their clinical judgement to select the most appropriate alternative medication to use. The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. Recommendations for managing a particular drug interaction may differ depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or whether a new concomitant medication is being initiated in a patient on a stable ARV regimen. For information regarding interactions between PIs and other ARV drugs, including dosing recommendations, refer to Tables 24c, 25a, and 25b. ![]() This table does not include interactions for fosamprenavir (FPV), nelfinavir (NFV), or tipranavir (TPV). ![]() The term “all PIs” refers to both unboosted ATV and ATV, darunavir (DRV), and lopinavir (LPV) boosted with either RTV or COBI. When information is available, interactions for boosted atazanavir (ATV) (with either ritonavir or cobicistat ) and unboosted ATV are listed separately. This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. ![]() Drug Interactions Between Protease Inhibitors and Other Drugs
0 Comments
Leave a Reply. |